Peter D. Reaven

This study identifies two independent BMI-associated variants at the GLP1R locus with distinct associations with T2D risk, suggesting heterogeneous genetic mechanisms.

The paper identifies 57 druggable targets for MASLD using genetic data and evaluates their therapeutic potential through Mendelian randomization and structural modeling.

This paper develops a genetically informed drug-repurposing pipeline for diabetes using EHRs and validates two anti-hypertensive classes as glycemic regulators.

This study conducts a trans-ancestry GWAS using chronic ALT elevation as a proxy for NAFLD, identifies 77 significant loci, and validates 17 SNPs with histology and imaging data, revealing genetic links to metabolic and inflammatory traits.

This study investigates the long-term cognitive and cerebrovascular effects of mild traumatic brain injury in rats, finding chronic cognitive dysfunction and altered vascular reactivity.

Multi-ethnic type 2 diabetes (T2D) meta-analysis of 228,499 cases and 1,178,783 controls finds 318 previously unreported loci, 804 expression-colocalized genes, and 13 SNP-by-T2D vascular-outcome interactions.